Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14 + and CD16 + monocytes driving an innate immune response-Reference-Cited by-同舟云学术

Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14 + and CD16 + monocytes driving an innate immune response

Published:2019-04-11 Issue:9 Volume:46 Page:627-636
ISSN:0303-6987
Container-title:Journal of Cutaneous Pathology
language:en
Short-container-title:J Cutan Pathol

Author:

Curry Jonathan L.¹²³^ORCID,Reuben Alexandre⁴,Szczepaniak‐Sloane Robert⁵,Ning Jing⁶,Milton Denái R.⁶,Lee Chi H.⁶,Hudgens Courtney³,George Saira²,Torres‐Cabala Carlos¹²^ORCID,Johnson Daniel⁷,Subramanya Sandesh³,Wargo Jennifer A.⁵,Mudaliar Kumaran⁸,Wistuba Ignacio I.³,Prieto Victor G.¹²,Diab Adi⁷,Tetzlaff Michael T.¹³^ORCID

Affiliation:

1. Pathology, Section of DermatopathologyThe University of Texas MD Anderson Cancer Center Houston Texas

2. DermatologyThe University of Texas MD Anderson Cancer Center Houston Texas

3. Translational Molecular PathologyThe University of Texas MD Anderson Cancer Center Houston Texas

4. Thoracic, Head and Neck Medical OncologyThe University of Texas MD Anderson Cancer Center Houston Texas

5. Surgical Oncology and Genomic MedicineThe University of Texas MD Anderson Cancer Center Houston Texas

6. BiostatisticsThe University of Texas MD Anderson Cancer Center Houston Texas

7. Melanoma Medical OncologyThe University of Texas MD Anderson Cancer Center Houston Texas

8. PathologyLoyola University Medical Center Maywood Illinois

Funder

National Institutes of Health

Publisher

Wiley

Subject

Dermatology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cup.13454

Reference42 articles.

1. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

2. Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

5. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

2. Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment;Biomedicines;2024-08-19

3. Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level;JAAD International;2024-06

4. Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review;Frontiers in Pharmacology;2023-12-12

5. Immune checkpoint inhibitor‐induced lichenoid drug eruption‐sparing scar burns;Australasian Journal of Dermatology;2023-11-27